REZOLUTE, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
REZOLUTE, INC. (RZLT) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $15.00 thousand for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-05-12
- REZOLUTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- REZOLUTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $0.00.
- REZOLUTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $15.00K, a 0.00% change year-over-year.
- REZOLUTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-03-31 was $6.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month |
|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $15.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $15.00K 10-Q · filed 2026-02-12 | |
| 2025-09-30 | $15.00K 10-Q · filed 2025-11-06 | ||
| 2025-03-31 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $15.00K 10-Q · filed 2026-05-12 |
| 2024-12-31 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $9.00K 10-Q · filed 2026-02-12 | |
| 2024-09-30 | $15.00K 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $27.00K 10-Q · filed 2025-02-12 | |
| 2023-09-30 | $14.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |